Sign in
Click here - to use the wp menu builder
Sign in
Welcome!
Log into your account
your username
your password
Forgot your password?
Password recovery
Recover your password
your email
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
Monday, December 23, 2024
Sign in / Join
Facebook
Instagram
Twitter
Vimeo
Youtube
Pharma Deals
Update
Oncology
Search
LATEST ARTICLES
Regulatory update
Daiichi’s mRNA COVID-19 Booster Vaccine Approved in Japan
pharmaquotient.com
-
2 August 2023
0
Regulatory update
China’s NMPA Accepts Astellas’ Biologics License Application for Zolbetuximab
pharmaquotient.com
-
1 August 2023
0
generic
Viatris Announces Launch of Breyna™ Generic Version of Symbicort®
pharmaquotient.com
-
31 July 2023
0
Weekly News Updates
Weekly Pharma News for the week ending 31-July-23
pharmaquotient.com
-
31 July 2023
0
Merger & Acquisition
Biogen to buy Reata Pharmaceuticals for up to $7.3 B
pharmaquotient.com
-
28 July 2023
0
Appointments
AstraZeneca appoints Sharon Barr as EVP of Biopharmaceutical R&D
pharmaquotient.com
-
28 July 2023
0
Appointments
Teva Appoints Dr. Angus Grant to Executive Vice President, Business Development
pharmaquotient.com
-
27 July 2023
0
Partnership agreement
Teva & Alvotech Provide Update on Strategic Biosimilars Partnership
pharmaquotient.com
-
24 July 2023
0
Regulatory update
Sandoz Receives Positive CHMP Opinion for Tysabri’s Biosimilar Natalizumab
pharmaquotient.com
-
24 July 2023
0
Partnership agreement
Alnylam Pharmaceuticals Partners with Roche to Develop and Commercialize RNAi Therapeutic Zilebesiran
Neha Tripathi
-
24 July 2023
0
1
...
5
6
7
Page 6 of 7
Most Popular
Neuralink’s Blindsight: A Breakthrough in Vision Restoration
20 September 2024
Theratechnologies Indicated Potential Supply Disruption for EGRIFTA SV® in Early 2025
17 September 2024
Kissei Pharmaceuticals Enters into a Drug discovery research collaboration agreement with Reborna Biosciences.
9 September 2024
Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
7 September 2024
Load more
Recent Comments
Rahul
on
US FDA Approves Zurzuvae For Postpartum Depression
Rahul
on
JNJ Expands Cancer Portfolio with TALVEY Approval
Ashish
on
Flagship Pioneering Partners with Pfizer to Bolster Development of Innovative Medicine for $50M upfront
Recent Comments